Pathogenesis and molecular mechanisms of chronic allograft nephropathy

Contributions to Nephrology

Volumn 139, Issue , 2003, Pages 187-204

  Ahsan, Nasimul ^a   Cheung, Joseph Y ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b WEIS CENTER FOR RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; APOPTOSIS; CHRONIC DISEASE; FIBROSIS; GRAFT REJECTION; HUMAN; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR;

APOPTOSIS; CHRONIC DISEASE; FIBROSIS; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0141922637     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071744     Document Type: Article

References (92)

1. Cecka JM: The UNOS Renal Transplant Registry; in Cecka, Terasaki (eds): Clinical Transplants 2001. Los Angeles, UCLA Immunogenetics Center, 2001, pp 1-18.
2. Weber KT: Fibrosis, a common pathway to organ failure: Angiotensin II and tissue repair. Semin Nephrol 1997;17:467-491.
3. Paul LC: Chronic allograft nephropathy - A model of impaired repair from injury? Nephrol Dial Transplant 2000;15:149-151.
4. Strutz F: Novel aspects of renal fibrogenesis. Nephrol Dial Transplant 1995;10:1526-1532.
5. Abo-Zenah H, Katsoudas S, Wild G, De Takats D, Shortland J, Brown CB, El Nahas AM: Early human renal allograft fibrosis: Cellular mediators. Nephron 2002;91:112-119.
6. Waller JR, Nicholson ML: Molecular mechanisms of renal allograft fibrosis.Br J Surg 2001;88:1429-1441.
7. Jain S, Furness PN, Nicholson ML: The role of transforming growth factor-β in chronic renal allograft nephropathy. Transplantation 2000;69:1759-1766.
8. Riggio RR, Haschemeyer R, Suthanthiran M, Cheigh J, Tapia L, Stubenbord W, Miller I, Stenzel KH: Predictability of renal allograft failure time in long-term survivors: A hypothesis. Transplant Proc 1985;17:2311-2313.
9. Massy ZA, Guijarro C, Weiderkehr MR, Ma JZ, Kasiske BL: Chronic renal allograft rejection: Immunologie and nonimmunologic risk factors. Kidney Int 1996;49:518-524.
10. Raine AEG: Does antihypertensive therapy modify chronic allograft failure? Kidney Int 1995;48(suppl):107-111.
11. Kassiske BL: Long-term post-transplantation management and complications; in Danovitch GM (ed): Handbook of Kidney Transplantation. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 182-220.
12. Kasiske BL, Kabil RSN, Lee HS, Rao KV: Histopathological findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991;80:514-524.
13. Sanfilippo F: Renal transplantation; in Sale GE (ed): The Pathology of Organ Transplantation. Boston, Butterworths, 1990, pp 51-101.
14. Mason DW, Morris PJ: Effector mechanisms in allograft rejection. Annu Rev Immunol 1986;4:119-145.
15. Barrientos A, Portoles J, Herrero JA, Torralbo A, Prats D, Gutierrez-Millet V, Blanco J: Glomerular hyperfiltration as a nonimmunologic mechanism of progression of chronic renal rejection. Transplantation 1994;57:753-756.
16. Cheigh JS, Mouradian J, Soliman M, Tapia L, Riggio RR, Stenzel KH, Rubin AL: Focal segmental glomerulosclerosis in renal transplants. Am J Kidney Dis 1983;2:449-455.
17. Habib R, Antigua C, Hinglais N, Gagnadoux MF, Broyer M: Glomerular lesions in the transplanted kidney in children. Am J Kidney Dis 1987;10:198-207.
18. Monga G, Mazzucco G, Messina M, Motta M, Quaranta S, Novara R: Intertubular capillary changes in kidney allografts: A morphologic investigation on 61 renal specimens. Mod Pathol 1992;5:125-130.
19. Vleming LJ, Baelde JJ, Westendorp RGJ, Daha MR, van Es LA, Bruijn JA: Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the interstitial extracellular matrix. Clin Nephrol 1995;44:211-219.
20. Matas AJ, Gillingham KJ, Payne WD, Najarian JS: The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994;57:857-859.
21. Almond PS, Matas A, Gillingham KJ, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752-757.
22. Takemoto S, Terasaki PI, Cecka JM, Cho YM, Gjertson DW: Survival of nationally shared HLAmatched kidney transplants from cadaveric donors. N Engl J Med 1992;327:834-939.
23. Tullius SG, Tinley NL: Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995;59:313-318.
24. Morris PJ: Factors influencing outcome in cadaveric renal transplantation. Br J Surg 1994;81:635-636.
25. Shoskes D, Cecka M: Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998;55:1697-1701.
26. Alexander JW, Bennet LE, Beren TJ: Effects of donor age on outcome of kidney transplantation: A two-year analysis of transplants reported to the United Network for Organ Sharing Registry. Transplantation 1994;57:1491-1499.
27. Burke JF, Pirsch JD, Ramos EL, Salomon DR, Stablein DM, Van Buren DH, West JC: Long-term efficacy and safety of cyclosporine in renal-transplant patients. N Engl J Med 1994;331:358-363.
28. Randhawa PS, Tsamandas AC, Magnone M, Jordan M, Shapiro R, Starzl TE, Demetris AJ: Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol 1996;20:306-312.
29. Connolly JO, Gane E, Higgins RM, O'Donnell PJ, Devlin J, Scoble JE, Williams R: Renal arteriopathy associated with FK506 therapy following liver transplantation. Nephrol Dial Transplant 1994;9:834-836.
30. Cuhaci B, Kumar MSA, Bloom RD, Prati B, Haussman G, Laskow DA, Alidoost M, Grotkowski C, Cahill K, Butani L, Sturgill BC, Pankewycz OG: Transforming growth factor-β levels in human allograft chronic fibrosis correlates with rate of decline in renal function. Transplantation 1999;68:785-790.
31. Wissing K, Abramowcs D, Breeders N, Vereerstraeten P: Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male with previous acute rejection. Transplantation 2000;70:464-472.
32. Brazy PC, Pirsch JD, Beizer FO: Factors affecting renal allograft function in long-term recipients. Am J Kidney Dis 1992;19:558-566.
33. Bostrom AG, Gohl RY, Morrissy P: Hyperhomocysteinemia in chronic renal transplant recipients. Graft 2000;3:195-204.
34. Norman JT, Clark IM, Garcia PL: Hypoxia promotes fibrogenesis in human renal fibroblast. Kidney Int 2000;58:2351-2366.
35. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
36. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2494-2508.
37. Kuncio GS, Neilson EG, Haverty T: Mechanisms of tubulointerstitial fibrosis. Kidney Int 1991;39:550-556.
38. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 1996;49:461-4(69
39. Furness PN: Extracellular matrix and the kidney. J Clin Pathol 1996;49:355-359.
40. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000;58:1841-1850.
41. Grandaliano G, Di Paolo S, Monno R, Stallone G, Ranieri E, Pontrelli P, Gesualdo L, Schena FP: Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: The role of coagulation and fibrinolysis in renal graft fibrosis. Transplantation 2001;72:1437-1443.
42. 1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells. Exp Nephrol 1993;1:343-350.
43. 1 and TNF-a on the plasminogen system of rat proximal tubular epithelial cells. J Am Soc Nephrol 1997;8:184-192.
44. Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem 1999;274:491-494.
45. Ye S, Humphries S, Henney A: Matrix metalloproteinases: Implication in vascular matrix remodeling during atherogenesis. Clin Sci 1998;94:103-110.
46. Salo T, Turpeeniemi-Hujanen R, Tryggvason K: Tumor-promoting esters and cell proliferation stimulate secretion of basement membrane (type IV) collagen-degrading metalloproteinase by human fibroblasts. J Biol Chem 1985;260:8526-8531.
47. Martin J, Knowlden J, Davies M, Williams JD: Identification and dependent regulation of human mesangial cell metalloproteinases. Kidney Int 1994;46:877-885.
48. Nagase H: Activation mechanisms of matrix metalloproteinases. J Biol Chem 1997;378:151-160.
49. Miyazaki M, Nishino T, Abe K, Furusu A, Koji T, Kohno S: Regulation of renal extracellular matrix metabolism; Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger 2003, vol 139, pp 141-155.
50. Murphy G, Willenbrock F: Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995;248:496-510.
51. Nakai A, Satoh M, Hirayoshi K, Nagata K: Involvement of the stress protein HSP47 in procollagen processing in the endoplasmic reticulum. J Cell Biol 1992;117:903-914.
52. Abe K, Ozono Y, Miyazaki M, Koji T, Shioshita K, Furusu A, Tsukasaki S, Matsuya F, Hosokawa N, Harada T, Taguchi T, Nagata K, Kohno S: Interstitial expression of heat-shock protein-47 and a-smooth muscle actin in renal allograft failure. Nephrol Dial Transplant 2000;15:529-535.
53. Boukhalfa G, Desmouliere A, Rondeau E, Gabbiani G, Sraer JD: Relationship between α-smooth muscle actin expression and fibrotic changes in human kidney. Exp Nephrol 1996;4:241-247.
54. Cohen GM: Caspases: The executioners of apoptosis. Biochem J 1997;326:1-16.
55. Faubion WA, Gores GJ: Death receptors in liver biology and pathobiology. Hepatology 1999;29:l-4f.
56. Razzaque MS, Ahsan N, Teguchi T: Role of apoptosis in fibrogenesis. Nephron 2002;90:365-372.
57. Hishikawa K, Nakaki T, Fujii T: Transforming growth factor-β induces apoptosis via connective tissue growth factor in human aortic smooth muscle cells. Eur J Pharmacol 1999;385:287-290.
58. Coleman AB, Momand J, Kane SE: Basic fibroblast growth factor sensitizes NIH 3T3 cells to apoptosis induced by cisplatin. Mod Pharmacol 2000;57:324-333.
59. Sporn MB, Roberts AB: Transforming growth factor-β: Recent progress and new challenges. J Cell Biol 1992;119:1017-1021.
60. Waltenberger J, Miyazono K, Funa K, Wanders A, Fellstrom B, Heldin CH: Transforming growth factor-β and organ transplantation. Transplant Proc 1993;25:2038-2040.
61. Ignotz RA, Endo T, Massague J: Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-β. J Biol Chem 1987;262:6443-6446.
62. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P et al: Transforming growth factor-β modulates the expression of collagenase and metallo-proteinase inhibitor. EMBO J 1987;6:1899-1904.
63. Border WA, Okuda S, Languino LR, Ruoslahti E: Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 1990;37:689-695.
64. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-β, mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993;44:313-321.
65. Paul LC, Saito K, Davidoff A, Benediktsson H: Growth factor transcripts in rat renal transplants. Am J Kidney Dis 1996;28:441-450.
66. Terrell TG, Working PK, Chow CP, Green JD: Pathology of recombinant human transforming growth factor-β in rats and rabbits. Int Rev Exp Pathol 1993;34:43-67.
67. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR: Connective tissue growth factor mediates transforming growth factor-β-induced collagen synthesis: Down-regulation by cAMP. FASEB J 1999;13:1774-1786.
68. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A: Tumor necrosis factor-a suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-15225.
69. 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor-2. Kidney Int 2001;59:579-592.
70. 1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996;49:1297-1303.
71. Nagano H, Nadeau KC,TakadaM, Kusaka M,Tilney NL: Sequential cellular and molecular kinetics in acutely rejecting renal allografts in rats. Transplantation 1997;63:1101-1108.
72. Mannon RB, Kopp JB, Ruiz P, Griffiths R, Bustos M, Platt JL, Klotman PE, Coffman TM: Chronic rejection of mouse kidney allografts. Kidney Int 1999;55:1935-1944.
73. 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996;50:1904-1913.
74. Weight SC, Bell PR, Nicholson ML: Renal ischaemia-reperfusion injury. Br J Surg 1996;83:162-170.
75. 1 expression in regenerating rat renal tubules following ischemic injury. Am J Physiol 1996;270:F500-F509.
76. Azuma H, Nadeau K, Takada M, Mackenzie HS, Tilney NL: Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney. Transplantation 1997;64:190-197.
77. Paul LC: Adverse effects of immunosuppressive drugs on long-term graft outcome. Transplant Proc 1998;30:4001-4f004.
78. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA: Molecular and structural consequences of early renal allograft injury. Kidney Int 2002;61:686-696.
79. Jain S, Bicknell GR, Nicholson ML: Tacrolimus has less fibrogenic potential than cyclosporine A in a model of renal ischemia-reperfusion injury. Br J Surg 2000;87:1563-1568.
80. Bicknell GR, Williams ST, Shaw JA, Pringle JH, Furness PN, Nicholson ML: Differential effects of cyclosporine and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. Br J Surg 2000;87:1569-1575.
81. Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP: Inhibition of angiotensinconverting enzyme in renal transplant recipients with hypertension. N Engl J Med 1983;308:377-381.
82. Dzau VJ: Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens 1994;12(suppl4):3-10.
83. Linger T, Gohlke P, Paul M, Rettig R: Tissue renin-angiotensin systems: Fact or fiction? J Cardiovasc Pharmacol 1991;18(suppl 2):20-25.
84. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993;3:1531-1540.
85. Razzaque MS, Azouz A, Shinagawa T, Taguchi T: Factors regulating the progression of hypertensive nephrosclerosis; Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger 2003, vol 139, pp 173-186.
86. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992;42:46-55.
87. Becker BN, Jacobson LM, Hullett DA, Radke NA, Oberley TD, Brazy PC, Kirk AD: Type 2 angiotensin II receptor expression in human renal allografts: An association with chronic allograft nephropathy. Clin Nephrol 2002;57:19-26.
88. 1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997;52:660-673.
89. Border WA, Okuda S, Languino LR, Ruoslahti E: Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 1990;37:689-695.
90. Tamaki K, Okuda S: Role of TGF-β in the progression of renal fibrosis; Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger 2003, vol 139, pp 44-65.
91. Kerins DM, Hao Q, Vaughan DE: Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV J Clin Invest 1995;96:2515-2520.
92. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.